| Source: |
| Type: |
| CD11b’s (also known as integrin αM or ITGAM). Markers CD14 and CD11b is one of the important characteristics of differentiation. High levels of CD11b are often noted in the tumor microenvironment. A high density of CD11b⁺ cells in the tumor microenvironment has been associated with adverse prognosis. For example, an abundance of MDSCs (which are CD11b⁺) is linked to immunosuppression, tumor progression, and resistance to therapies. High levels of CD11b⁺ cell infiltration have been correlated with: -Faster tumor progression. -Increased metastasis. -Reduced response to immunotherapies. |
| 7183- | CHA, | The SUV39H1 inhibitor chaetocin induces differentiation and shows synergistic cytotoxicity with other epigenetic drugs in acute myeloid leukemia cells |
| - | in-vitro, | AML, | HL-60 | - | in-vitro, | AML, | KG-1 | - | in-vitro, | lymphoma, | U937 |
| 7011- | Fuc, | ATO, | VitA,RetA, | Fucoidan enhances the therapeutic potential of arsenic trioxide and all-trans retinoic acid in acute promyelocytic leukemia, in vitro and in vivo |
| - | NA, | APL, | APL NB4 | - | vitro+vivo, | NA, | NA |
| 4936- | PEITC, | PEITC treatment suppresses myeloid derived tumor suppressor cells to inhibit breast tumor growth |
| - | in-vivo, | BC, | MDA-MB-231 |
| 1345- | SK, | The Critical Role of Redox Homeostasis in Shikonin-Induced HL-60 Cell Differentiation via Unique Modulation of the Nrf2/ARE Pathway |
| - | in-vitro, | AML, | HL-60 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:1067 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid